The Patent Finder

Aeterna Zentaris GmbH

Also on record
Records under this name other than the patents Aeterna Zentaris GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.

Back to Aeterna Zentaris GmbH

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,710,089Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
Lapsed on the fee record
Ended Apr 29, 2026 · USPTO record
Lapsed on the fee recordEnded Apr 29, 2026USPTO record
US 8,669,091Microorganisms as Carriers of Nucleotide Sequences Coding for Antigens and Protein Toxins, Process of Manufacturing and Uses Thereof
Formerly held
Lapsed on the fee record
Ended Mar 11, 2026 · High confidence
Lapsed on the fee recordEnded Mar 11, 2026High confidence
US 8,546,435Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
Lapsed on the fee record
Ended Oct 1, 2025 · High confidence
Lapsed on the fee recordEnded Oct 1, 2025High confidence
US 7,887,817Process for preventing protozoal diseases
Term ended
Term ended Dec 22, 2024 · USPTO record
Term endedTerm ended Dec 22, 2024USPTO record
US 8,551,977Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
Term ended
Term ended Jan 31, 2024 · USPTO record
Term endedTerm ended Jan 31, 2024USPTO record
US 7,214,662Injectable solution of an LHRH antagonist
Formerly held
Term ended
Term ended Oct 29, 2023 · USPTO record
Term endedTerm ended Oct 29, 2023USPTO record
US 7,790,686Injection solution of an LHRH antagonist
Formerly held
Term ended
Term ended Oct 28, 2023 · USPTO record
Term endedTerm ended Oct 28, 2023USPTO record
US 8,389,497Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
Formerly held
Term ended
Ended no later than Jul 30, 2023 · USPTO record
Term endedEnded no later than Jul 30, 2023USPTO record
US 6,861,409Growth hormone secretagogues
Term ended
Term ended Aug 1, 2022 · USPTO record
Term endedTerm ended Aug 1, 2022USPTO record
US 7,297,681Growth hormone secretagogues
Term ended
Term ended Aug 1, 2022 · USPTO record
Term endedTerm ended Aug 1, 2022USPTO record
10 of 62 patents shown.
Pro members see all 62.
Pro members: see all 62 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited